Our Story
Australia Has World-Class Science
Yet too often, promising vaccine and infectious disease innovations struggle to translate into commercial outcomes as traditional grants rarely support early to mid-stage product development – the so-called ‘valley of death’ – leaving them unable to attract follow-on funding and investment, and ultimately failing to reach the patients and communities that need them most.
Biointelect Venturer Will Boost That Trajectory
Funded by $32.9 million from the Australian Government, under the Medical Research Future Fund (MRFF) 2024 BioMedTech Incubator Grant Opportunity, Biointelect Venturer is a new national virtual incubator dedicated to advancing important early-stage Australian innovations for the prevention of infectious disease – vaccines, immunotherapies, and related technologies – from concept to commercial and investment readiness.
By providing the right funding, mentorship, and strategic frameworks, it will guide Australian innovators to cross the translation gap and bring new health technologies to life for the prevention of infectious diseases.
A National Call for Enhanced Collaboration
Biointelect Venturer builds on the momentum of the Australian Vaccine and Value Chain Conference (AVVCC 2024), where more than 215 leaders across government, academia, and industry called for national coordination and clearer translational pathways to unlock Australia’s vaccine potential.
The incubator also directly aligns with priorities outlined in the National Science and Research Priorities (2024) and the National Immunisation Strategy 2025–2030, which highlight the need to strengthen sovereign capability, improve pandemic preparedness, and foster public–private partnerships to accelerate innovation.
By connecting these strategies to practice, the incubator provides the structured mechanisms needed to translate discovery into deployable products — helping to ensure Australia remains a trusted global partner in vaccine innovation.
Our Long-Term Ambition
Biointelect Venturer is not just about individual projects – it’s about building national capability and positioning Australia as a world-leading catalyst for transformative Australian vaccine and infectious disease innovation for global health impact.
By fostering collaboration across Australia’s vaccine and biotech ecosystem, as well as global networks, and nurturing globally competitive SMEs, the incubator will ensure that home-grown innovations become solutions that reach patients and communities for the benefit of all Australians and global public health.
Our long-term goal is to attract diversified funding that will support a sustainable model to effectively maintain the Biointelect Venturer incubator beyond the government grant.
